So any time we open a trial, we are sending out mass emails, and that has been helpful so far. That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. What have you found, and how have you managed to offset their concerns? Shilpa Gupta, MD: Thanks, Dale. DC USA What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. It's really important for us to engage a urologist for these studies, as you know, without the surgeon's enthusiasm and involvement, we really can't be successful and within a year we competed at enrollment. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. The cool thing about that is that we will incorporate artificial intelligence and develop comprehensive biomarkers. Yes. For our GU group, we have several lists for everybody out in the community, including urologists and medical oncologists. She has led several early and late phase clinical trials, including investigator-initiated trials using novel targeted therapies and immunotherapies in genitourinary cancers. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. Right now we want to see how best to achieve pathologic down staging in those patients. Thanks, Dale. She completed Hematology-Oncology fellowship at Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship there in Dr. Marja Nevalainen’s laboratory. In that trial, we are prospectively selecting based on the biomarker. Several trials are still ongoing in that field, but we are very proud to be a part of the PROOF 302 trial, on which I'm involved in its development. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. See the complete profile on LinkedIn and discover shilpa’s connections and jobs at similar companies. Apple Podcasts    |    Google Podcasts    |    SoundCloud    |    Spotify    |    Blubrry    |    Stitcher. 9500 Euclid Avenue, Cleveland, Ohio 44195 |. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. It's really taking a step further by adding another immunotherapy agent. 2001, Genitourinary Cancers: Bladder Cancer, prostate Cancer, Kidney Cancer, Testicular Cancer, (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. Shilpa has 6 jobs listed on their profile. Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. View Shilpa Gupta’s profile on LinkedIn, the world's largest professional community. As you noted, this is a Bladder Cancer Signal Seeking Trial I. Subscribe:    Shilpa a 6 postes sur son profil. Do we do that for other diseases? Shilpa Gupta, MD: Yes. Are they leery to enroll in trials that delay surgery? Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. We have the cohort of our trial, the BLASST-1, which is immunotherapy and chemotherapy and Dr. Peter Black, who's a collaborator from Vancouver, he has a cohort of his patients who received only gem-cis chemotherapy and Dr. Andrea Necchi from Italy has done single-agent pembrolizumab trial in the same setting. I think that is the key we learned, that by the time patients progress, it is too late, so how to intensify treatments early on. Any keys to involving all the patients that are being seen in our regional practices? More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. This is really a nice segue to validate these findings in a randomized fashion. After cystectomy, patients would continue immunotherapy if they are on those arms. WI USA We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Dr. Shilpa has 3 jobs listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Dr. Gupta  is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO). The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. shilpa has 1 job listed on their profile. Shilpa has 3 jobs listed on their profile. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. Do we have any efforts ongoing for different histologies? New Delhi, You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. Shilpa has 1 job listed on their profile. Shilpa Gupta, MD: Yes, absolutely. So these results were very promising, overall. Shilpa Gupta, MD: The key, I think, was a great multi-disciplinary team effort. Shilpa Gupta, M.D. Have a great day. Shilpa Gupta, MD: Yeah, I think the team here is really fantastic. Shilpa Gupta, MD: Yes, absolutely. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Hematology-Oncology Philadelphia, Shilpa Gupta, MD: But we do. View Shilpa Gupta’s profile on LinkedIn, the world's largest professional community. Please join us again soon. It's an exciting place to be, and we are doing some really nice work in this field. 2010, Fellowship - Medical College of Wisconsin As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. Dr. Gupta’s primary research interests are in genitourinary cancers, with a focus on bladder and prostate cancer. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. India If patients have residual disease, which has invaded the muscle at the time of either nephroureterectomy or cystectomy, and if they expressed the FGFR3 biomarker, then they're randomized to an FGFR3-inhibitor or placebo, which is reasonable as there is really no standard for those patients. PA USA After completion of her fellowship in 2011, Dr. Gupta was appointed as an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics where she had clinical, teaching and research responsibilities and stayed on staff until 2015. But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. What was the key to the success in getting this trial to happen? So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. We enrolled 41 patients between February, 2018 and June, 2019 with muscle-invasive bladder cancer. Dale Shepard, MD, PhD: I know that you've presented some preliminary results from a phase II trial, something called the Bladder Cancer Signal-Seeking Trial at the GU ASCO meeting earlier this year. We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. * In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry. Dr. Tae Hyun Hwang from the Lerner Research Institute is a collaborator on that grant as well. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. Shilpa Gupta, MD: Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Dale Shepard, MD, PhD: How do you see this moving forward? The key, I think, was a great multi-disciplinary team effort. What about the more unusual histologies? How about patients? Yeah, absolutely. Do we have any efforts ongoing for different histologies? What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. I'm your host, Dr. Dale Shepard, a medical oncologist here at Cleveland Clinic, overseeing our Taussig Phase I and Sarcoma Programs. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. Related Videos Featuring Shilpa Gupta, MD. View the profiles of professionals named "Shilpa Gupta" on LinkedIn. Yeah, I think the team here is really fantastic. Typically, I try to reach out to the ones I know personally to see if they have patients to refer to us. Shilpa has 8 jobs listed on their profile. Shilpa has 3 jobs listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Shilpa Gupta, M.D. Yeah, and I think the key is just being available, so if people call or send an email and ask if we have something available, to reach out and collaborate with people, so I think that helps. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. But I think as an institutional-wide effort, it would be good to have a disease-specific flyer go out to these. Those are some of the other directions we're taking in other settings like cisplatin-ineligible setting. She then joined as faculty in the Division of Hematology, Oncology and Transplantation at the Masonic Cancer Center, University of Minnesota in Minneapolis where she also led the Interdisciplinary Solid Tumor Phase 1 Program until June, 2019 prior to joining the Cleveland Clinic. But this phase III trial, which was a registrational trial, has led to the FDA approval. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Not every place has all these good combinations. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. What have you found, and how have you managed to offset their concerns? Shilpa Gupta has 2 jobs listed on their profile. It was pretty remarkable. Yes, absolutely. Preventing and Treating Hereditary Colorectal Cancer. Dale Shepard, MD, PhD: You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. As such, gifts of substantial value are generally prohibited. Cleveland Clinic Cancer Center oncologist Shilpa Gupta, MD discusses promising findings in the treatment of advanced bladder cancer in this week's Cancer Advances podcast. Im Profil von Shilpa Gupta sind 3 Jobs angegeben. The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. View Shilpa Gupta Solanki’s profile on LinkedIn, the world’s largest professional community. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Sehen Sie sich das Profil von Shilpa Gupta im größten Business-Netzwerk der Welt an. So thanks so much for joining us today. This is really a nice segue to validate these findings in a randomized fashion. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. She's here today to discuss clinical trials in bladder cancer. 2007, Internship - RCH Government Hospital Certainly people who might be listening may not be associated with a larger institution, and they may be needing to partner with somebody to send patients. We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. Shilpa has 1 job listed on their profile. Thank you for listening. This was an investigator-initiated trial that I led. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. Yeah. Shilpa has 2 jobs listed on their profile. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. Yeah, sure. Shilpa, can you tell me a little bit about your role here at Cleveland Clinic? Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? It's quite exciting. It does seem to be a common question, doesn't it? See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Fellowship - Jefferson Medical College of Thomas Jefferson University View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. She also provides an update on additional in-progress clinical trials and what’s on the horizon for bladder cancer research. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. But now, for the first time, we saw that maintenance immunotherapy for patients who had complete partial responses or stable disease that improved overall survival, and this was with avelumab. What was the key to the success in getting this trial to happen? Public Health Service-Reportable Financial Conflicts of Interest. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Shilpa Gupta, MD: Yes, absolutely. Shilpa shilpa | Dudley, England, United Kingdom | Student at University of Wolverhampton | 1 connection | See Shilpa's complete profile on Linkedin and connect View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Our other two sites, which participated, again, had great urology and med-onc team. More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. Yeah. 2011, Fellowship - Jefferson Medical College of Thomas Jefferson University Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. Dale Shepard, MD, PhD: It does seem to be a common question, doesn't it? How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? Not every place has all these good combinations. Shilpa has 3 jobs listed on their profile. More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. CT USA It's an exciting place to be, and we are doing some really nice work in this field. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. 9500 Euclid Avenue, Cleveland, Ohio 44195 |. Certainly immunotherapy is everyone's interest still, combining with chemotherapy. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. That's an excellent question, Dale. Genitourinary Oncology Research Fellowship Philadelphia, I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. Internal Medicine Farmington, Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. Based on this trial, we actually got the Department of Defense Idea Award for this year, looking at immune biomarkers, like resistance and response biomarkers to immunotherapy. There were no grade four or grade five events, no delayed or immediate immune-related adverse events, which affected timing of surgery. Dale Shepard, MD, PhD: How about patients? View Dr. Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. Thank you for joining us for another episode of Cancer Advances. Faridabad, Patients received four cycles of gemcitabine and cisplatin with nivolumab added on day eight of each cycle. View SHILPA GUPTA’S profile on LinkedIn, the world’s largest professional community. SHILPA has 6 jobs listed on their profile. It was pretty remarkable. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. Shilpa has 7 jobs listed on their profile. Is there any particular thing you're looking forward to? Thanks for the opportunity. Dr. Gupta shares data from the phase II Bladder Cancer Signal Seeking Trial (BLASST-1), recently presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. Shilpa has 8 jobs listed on their profile. Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. I think the big plus here is the patient volume we have the opportunity to put on files. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Dale Shepard, MD, PhD: Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. That was a phase II trial. PA USA Hematology-Oncology Washington, Dr. Gupta has been appointed to serve on the ASCO Annual Meeting Scientific Program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce. Would love to. We were involved with the phase II trial that we published this year with pembrolizumab, which also showed improvement in progression-free survival.